Adenocarcinoma of the esophagus: controversies and consensus

David H. Ilson

Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Correspondence to: David H. Ilson, MD, PhD. Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 300 E. 66th St., BAIC Room 1031, New York, NY 10065, USA. Email: ilsond@mskcc.org.

Abstract: Esophageal cancer, the sixth most common cause of cancer globally, is characterized by the development of early systemic metastatic disease. Adenocarcinoma of the esophagus and gastroesophageal junction (GEJ) is more common in the West. Preoperative chemotherapy or chemoradiotherapy is employed for locally advanced disease with contemporary studies suggesting higher rates of curative resection and reduced rates of local recurrence with the combination of chemotherapy and radiation therapy given prior to surgery. The role of targeted agents and PET scan imaging in preoperative therapy is under active investigation.

Keywords: Esophageal adenocarcinoma; chemoradiotherapy; chemotherapy; PET scan

Submitted Sep 01, 2017. Accepted for publication Sep 07, 2017.
doi: 10.21037/cco.2017.09.02

View this article at: http://dx.doi.org/10.21037/cco.2017.09.02

Introduction

Esophageal cancer is an uncommon disease in the West, and will be diagnosed in 16,940 patients and account for 15,690 deaths in the US in 2017 (1). Squamous cell cancer is the more common histology globally, whereas adenocarcinoma is the most common histology in Western countries, related to reflux-associated Barrett’s esophagus. An ongoing increase in adenocarcinoma of the distal esophagus and gastroesophageal junction (GEJ) has occurred over the past 4 decades (2,3). With nearly 500,000 cases seen annually around the world, esophageal cancer is the sixth leading cause of cancer related death (4). Metastatic disease is present in half of patients at diagnosis, and patients with local regional disease develop metastatic disease in the majority of cases. Given the anatomy of the mediastinum and GEJ, the risk of incomplete surgical resection and local tumor recurrence is significant. Neoadjuvant or preoperative therapy is now routinely included given the poor outcomes with surgical management alone.

Surgical treatment of esophageal cancer

Resection of the esophagus with en bloc lymphadenectomy is the cornerstone of curative treatment for patients with locally advanced esophageal cancer (5). Treatment in high-volume centers with experienced surgeons and the availability of critical-care support are associated with improved outcomes and lower morbidity and mortality (6,7).

A transthoracic esophagectomy with two-field lymph node dissection and gastric conduit reconstruction is the preferred procedure for resection of esophageal cancer (8,9). Transhiatal esophagectomy, without thoracotomy was designed to reduce postoperative morbidity and mortality by avoiding thoracotomy (10,11). A randomized clinical trial, comparing an extended transthoracic resection with a transhiatal approach showed that transhiatal esophagectomy was associated with lower morbidity and shorter intensive care unit and hospital stay compared to transthoracic esophagectomy (12). Compared with transhiatal resection, transthoracic esophagectomy for esophageal adenocarcinoma indicated a trend towards better 5-year survival (13,14). Minimally invasive esophagectomy, and more recently robotically assisted esophagectomy, are emerging as surgical alternatives to open esophagectomy (15-18).

For clinical T2N0 esophageal cancer, surgery alone is regarded as a standard treatment approach without neoadjuvant therapy (19-21). Current preoperative staging of patients with T2N0 esophageal cancer may lead to clinical understaging in a substantial proportion of patients.
In addition, trials have not confirmed a clear survival benefit of a preoperative therapy compared to a surgery alone for T2N0 esophageal cancer (21,25-28). There is ongoing controversy about treating these patients with preoperative therapy.

**Pre-operative chemotherapy**

Neoadjuvant or preoperative therapy has been evaluated largely in clinical T3 or node positive disease. Select controlled trials evaluating the use of preoperative chemotherapy in esophageal cancer are listed in Table 1. Perioperative chemotherapy for esophageal adenocarcinoma and SCC failed to improve any outcome compared to surgery alone in US Intergroup Trial 113 (32). This study administered three pre- and two postoperative cycles of infusional 5-FU combined with cisplatin (CF). Low rates of R0 resection were reported with (63%) or without chemotherapy (59%), with high rates of local tumor recurrence (27–29%) after curative surgery, and 5-year overall survival of 20% with or without chemotherapy. A modest 6% improvement in 5-year overall survival was reported at long-term follow-up (17% to 23%) (35). The Federation Nationale des Centres de Lutte Contre le Cancer/Federation Francophone de Cancerologie Digestive (FNCLCC/FFCD) French trial treated 224 patients with adenocarcinoma of the lower esophagus, GEJ junction, or stomach with pre- and postoperative CF (36). Improvements in R0 resection (13%) and survival (13%) were reported for preoperative chemotherapy. This trial also reported high rates of local tumor recurrence after surgery (29–36%).

The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial of perioperative chemotherapy in gastroesophageal cancer in the UK reported a survival benefit for perioperative chemotherapy (29). Patients with clinical stage II or higher adenocarcinomas of the lower third of the esophagus, GEJ, or stomach were treated, and the majority of the 503 patients treated (74%) had gastric primaries. Surgery alone was compared to 3 cycles of epirubicin, CF, and infusional 5-FU (ECF) pre- and 3 cycles post-surgery. Tumor downstaging was modest with chemotherapy, with more T1–2 tumors in the chemotherapy group compared to surgery alone (52% vs. 37%) and more N0–1 tumors (84% vs. 72%). Similar numbers of patients had N0 disease with or without chemotherapy (31–27%). Progression free and overall survival were superior for the chemotherapy arm, with a 5-year overall survival increased from 23% to 36%.

**Table 1 Results of phase III pre- or peri-operative chemotherapy trials in esophageal and GEJ cancer**

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Histology</th>
<th>Number</th>
<th>R0 rate</th>
<th>Survival</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECF + surgery</td>
<td>Adeno</td>
<td>250</td>
<td>69%</td>
<td>24 months</td>
<td>5-year 36%</td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td>253</td>
<td>66%</td>
<td>20 months</td>
<td>5-year 23%</td>
</tr>
<tr>
<td>5FU/Cis + surgery</td>
<td>Adeno</td>
<td>109</td>
<td>87%</td>
<td>NS</td>
<td>5-year 38%</td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td>110</td>
<td>74%</td>
<td>NS</td>
<td>5-year 24%</td>
</tr>
<tr>
<td>ECX + surgery</td>
<td>Adeno</td>
<td>446</td>
<td>67%</td>
<td>25.8 months</td>
<td>3-year 42%</td>
</tr>
<tr>
<td>5FU/Cis + surgery</td>
<td>Adeno</td>
<td>451</td>
<td>60%</td>
<td>24.2 months</td>
<td>3-year 39%</td>
</tr>
<tr>
<td>5FU/Cis + surgery</td>
<td>Adeno + SCC</td>
<td>213</td>
<td>62%</td>
<td>14.9 months</td>
<td>3-year 23%</td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td>227</td>
<td>59%</td>
<td>16.1 months</td>
<td>3-year 26%</td>
</tr>
<tr>
<td>Pre-op 5FU/Cis + surgery</td>
<td>Adeno + SCC</td>
<td>400</td>
<td>60%</td>
<td>16.8 months</td>
<td>5-year 23%</td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td>402</td>
<td>54%</td>
<td>13.3 months</td>
<td>5-year 17%</td>
</tr>
</tbody>
</table>

Adeno, adenocarcinoma; Cis, cisplatin; ECF, epirubicin, cisplatin, 5-fluorouracil; ECX, epirubicin, cisplatin, capecitabine; NS, not stated; SCC, squamous cell carcinoma; GEJ, gastroesophageal junction.
with chemotherapy. Based on this trial, perioperative ECF became a new care standard in Western Europe and the US in esophagogastric cancer.

**Concern about the adequacy of preoperative chemotherapy alone in esophageal and GEJ cancer patients continues given persistently lower rates of R0 resection for esophageal and GEJ cancers reported in contemporary trials.** Two recent trials from the UK treated 1,900 patients with either preoperative CF or ECF, including 1,600 patients with esophageal and GEJ adenocarcinoma (30,31). Relatively low rates of R0 resection of 57–67% were reported for esophageal and Siewert I GEJ cancers, compared to 87% for more distal gastric cancers, on these studies using preoperative chemotherapy. These results have continued the debate about the potential need to include preoperative radiation therapy to ensure RO resection for patients with tumors involving the esophagus and GEJ.

Results of the FLOT4 trial, which compared treatment of GE junction and gastric cancer with perioperative ECF to a regimen combining docetaxel with infusional 5-FU and oxaliplatin (FLOT) in over 700 patients, were recently reported in abstract form (37). FLOT resulted in superior rates of R0 resection compared to ECF (77% to 84%), and improved progression free survival (18 to 30 months), and overall survival (35 to 50 months) with an estimated improvement in 5-year overall survival from 36% to 45%. FLOT may emerge as a new standard of care in the preoperative chemotherapy management of esophagogastric adenocarcinoma.

**Post-operative chemotherapy**

In East Asia, trials in resected gastric cancer have administered post-operative chemotherapy. However, fewer than 10% of tumors occur in the proximal stomach/GEJ, and it is unclear whether or not these results are applicable to Western patients with esophageal and GEJ cancers. Two trials, treating 2,000 patients with gastric cancer after D2 resection reported 9–10% improvements in 5-year survival for treatment with either 6 months of capecitabine plus oxaliplatin, or 1 year of S-1 (38,39).

**Preoperative chemoradiotherapy**

The landmark Radiation Therapy Oncology Group (RTOG) Trial 8501 combined 50 Gy of radiation therapy with concurrent CF for 2 cycles during and 2 cycles after radiation therapy, compared to radiation therapy alone (40). Long-term survival was achieved with chemoradiotherapy without surgery. No patients treated with radiation therapy alone survived beyond 3 years. At long-term follow-up, 26% of patients treated with combined chemoradiotherapy achieved 5-year survival, with the majority of patients treated on this trial having squamous cancers but adenocarcinoma patients also achieving a lesser but still measurable long-term survival (41). High rates of either local recurrence or persistence of disease after chemoradiotherapy were reported (52%), and the need for surgery after chemoradiotherapy has been continually debated.

Preoperative chemoradiation followed by surgery has been evaluated extensively in esophageal cancer. Selected randomized trials are outlined in Table 2. Largely underpowered early trials comparing pre-operative chemoradiation followed by surgery to surgery alone, had mixed results. Chemotherapy and radiotherapy followed by surgery for esophageal and GEJ cancers emerged as standard of care based on results from the Chemoradiotherapy for Oesophageal Cancer followed by Surgery Study (CROSS) (47,48). CROSS compared surgery alone to preoperative weekly carboplatin, paclitaxel, and 41.4 Gy of radiotherapy followed by surgery in esophageal and GEJ adenocarcinoma and squamous cell carcinoma. The majority of patients treated on trial had adenocarcinoma. In addition to increasing 5-year survival from 33% to 47% with combined preoperative chemoradiotherapy, higher rates of R0 resection (92% versus 69%) and relatively low rates of local recurrence (14% versus 34%) were reported with preoperative therapy compared to surgery alone. A pathologic complete response rate of 23% for adenocarcinoma was reported. The inclusion of squamous cancer patients makes interpretation of the results less clear: overall survival for adenocarcinoma was improved from 27.1 to 43.2 months (HR 0.73) with a more robust impact for squamous cancer (27.1 to 81.6 months, HR 0.48). A survival benefit was suggested more for clinical node negative patients (HR 0.50) compared to clinical node positive patients (HR 0.81). The short duration of chemotherapy administered during this treatment, 5 weeks of carboplatin and paclitaxel, has been criticized as inadequate systemic therapy.

Preoperative chemoradiotherapy added to surgery in earlier clinical stage T1-2N any or clinical T3N0 cancers have not clearly improved survival compared to surgery alone, including one recent trial from France (21). The majority of patients on this trial (72%) had squamous cancers. The high
93% R0 resection rate in the surgery-alone arm was not improved with pre-operative chemoradiation. Postoperative mortality was significantly increased in the chemoradiation arm (11.1% vs. 3.4%).

Additional preoperative chemotherapy cycles beyond 2 cycles of CF chemotherapy (30), the addition of epirubicin to FP (30), or the addition of induction chemotherapy cycles prior to chemoradiotherapy (35) all have failed to improve survival, arguing that the benefit from preoperative chemotherapy may be achieved with relatively brief chemotherapy exposure. The addition of targeted agents to chemoradiotherapy, including two trials adding the EGFR-targeted agent cetuximab to chemoradiotherapy (49,50), failed to improve any outcome. A pilot trial combining the vascular endothelial growth factor (VEGF) targeted agent bevacizumab with chemoradiotherapy (51), and a randomized trial adding bevacizumab to preoperative chemotherapy (31) also failed to improve outcome. A pilot trial combining the vascular endothelial growth factor (VEGF) targeted agent bevacizumab with chemoradiotherapy (51), and a randomized trial adding bevacizumab to preoperative chemotherapy (31) also failed to improve outcome. A pilot trial combining the vascular endothelial growth factor (VEGF) targeted agent bevacizumab with chemoradiotherapy (51), and a randomized trial adding bevacizumab to preoperative chemotherapy (31) also failed to improve outcome. A pilot trial combining the vascular endothelial growth factor (VEGF) targeted agent bevacizumab with chemoradiotherapy (51), and a randomized trial adding bevacizumab to preoperative chemotherapy (31) also failed to improve outcome.

An ongoing trial in GEJ and gastric cancer, TOPGEAR, is comparing the use of perioperative chemotherapy with ECF with or without preoperative radiotherapy (NCT 01924819). Other trials evaluating preoperative chemoradiotherapy with or without radiotherapy in esophageal and GEJ cancers include a German trial comparing preoperative 5-FU, oxaliplatin, and docetaxel vs. the CROSS approach (NCT02509286), and an Irish study comparing preoperative chemotherapy with ECF to CROSS (NCT01726452).

A trial attempting to compare pre-operative chemoradiation to pre-operative chemotherapy was reported by the German POET trial (PreOperative Chemotherapy or Radiochemotherapy in Esophago Gastric Adenocarcinoma Trial). Patients with GEJ adenocarcinomas were randomized to either 5-FU/leucovorin/CF followed by surgery or 5-FU/leucovorin/CF followed by chemoradiation with CF/etoposide and then surgery (52). The trial closed due to poor accrual at only 118 patients and was underpowered to achieve any definitive conclusion. Patients treated with chemoradiation had a higher pathologic complete response rate (15.6% vs. 2%) and node negative status at surgery (64.4% vs. 36.7%) compared to treatment with chemotherapy alone. There were trends toward improved local control (76.5% vs. 59%) and 3-year overall survival (47.4% vs. 27.7%) for the chemoradiation group which did not reach statistical significance.

A similar non-significant trend toward improved outcomes with pre-operative chemoradiation over

| Regimen   | Histology       | Number | R0 rate | Survival
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Median</td>
</tr>
<tr>
<td>CRT</td>
<td>Adeno + SCC</td>
<td>50</td>
<td>45%</td>
<td>16.9 months</td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td>50</td>
<td>45%</td>
<td>17.6 months</td>
</tr>
<tr>
<td>CRT</td>
<td>Adeno</td>
<td>58</td>
<td>NS</td>
<td>16 months</td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td>55</td>
<td>NS</td>
<td>11 months</td>
</tr>
<tr>
<td>CRT</td>
<td>SCC</td>
<td>143</td>
<td>81%</td>
<td>18.6 months</td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td>139</td>
<td>69%</td>
<td>18.6 months</td>
</tr>
<tr>
<td>CRT</td>
<td>Adeno + SCC</td>
<td>128</td>
<td>80%</td>
<td>22.2 months</td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td>128</td>
<td>59%</td>
<td>19.3 months</td>
</tr>
<tr>
<td>CRT</td>
<td>Adeno + SCC</td>
<td>30</td>
<td>NS</td>
<td>4.5 years</td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td>26</td>
<td>NS</td>
<td>1.8 years</td>
</tr>
<tr>
<td>Preop CRT</td>
<td>Adeno + SCC</td>
<td>178</td>
<td>92%</td>
<td>49.4 months</td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td>188</td>
<td>69%</td>
<td>24.0 months</td>
</tr>
</tbody>
</table>

CRT, preoperative chemoradiation.
Chemotherapy was also suggested in the meta-analysis reported by Sjoquist et al., which revealed an all-cause mortality HR of 0.88 (95% CI: 0.76–1.01, P=0.07) favoring chemoradiation (53).

**Post-operative chemoradiation**

In the US, one additional alternative is post-operative chemoradiation for GEJ and gastric cancers undergoing up front resection, based on the results of the Intergroup 116 trial (54,55). This trial randomized 556 patients (20% of whom had tumors that involved the GEJ) to adjuvant chemotherapy and chemoradiation with bolus 5-FU/leucovorin or to observation alone following surgery. Overall survival was improved by 10% favoring postoperative therapy. This trial had relatively poor surgical quality, with 54% of patients having less than a D1 or D2 resection. Because many patients after esophagogastrectomy fail to recover to the point of tolerating post-operative therapy, and given the potential downstaging achieved by preoperative therapy, postoperative chemoradiotherapy for esophageal or GEJ cancers is rarely applied.

**Salvage surgery after neoadjuvant chemoradiotherapy**

For patients with a poor performance status or with advanced age and medical comorbidities, given a potentially high risk for either mortality or severe complications from esophagectomy, definitive chemoradiotherapy without surgical resection is considered (56,57). Local recurrence rates after definitive chemoradiotherapy are high and are observed in 40–75% of patients (58-60). Patients with local regional recurrence after definitive chemoradiotherapy may be considered for salvage surgery (56). After salvage surgery, a higher mortality rate is reported as well as increased rates of anastomotic leak and pulmonary complications (56).

**Targeted agents, genomic analysis, and PET scan imaging**

Targeted therapy trials have largely focused on the VEGF pathway, and receptor associated tyrosine kinase pathways such as EGFR, HER2, and MET. In metastatic disease, response and survival benefits have been observed in phase III trials of the agent ramucirumab targeting the VEGFR2 receptor, and trastuzumab targeting the HER2 receptor (61-63). As noted above, trials combining the EGFR inhibitors cetuximab or the VEGF inhibitor Bevacizumab have failed to improved outcome when added to either chemoradiotherapy or preoperative chemotherapy (31,49,50). Results from a trial combining trastuzumab with preoperative chemoradiotherapy in HER2 positive esophageal and GEJ cancer are pending.

Genomic analyses of gastroesophageal cancers using broad genomic screening for gene mutation, amplification, and deletions have recently been reported. Remarkably similar genomic profiles have emerged from genomic studies evaluating Western and Asian patients with gastric cancer (64,65). Molecular subgroups identified in US studies under The Cancer Genome Atlas (TCGA) project, include (I) genomically unstable tumors with higher rates of receptor associated tyrosine kinase pathway gene amplification (HER2, EGFR, MET, FGFR), high rates of p53 mutation, and amplification of VEGFA and cell cycle pathways; (II) genomically stable tumors with relatively few mutations and presence of CDH-1 and RHO-A mutation; (III) tumors with higher rates of gene hypermethylation leading to a higher mutation burden with high rates of microsatellite instability (MSI); and (IV) tumors associated with EBV infection and amplification of potential immune related pathways including over expression of PDL-1 and PDL-2 ligands. Correlating anatomic location and conventional histology, the vast majority of esophageal and GEJ adenocarcinomas fall under the genomically unstable category and 50% of distal gastric cancers fall into this category (66). Therapeutic implications of these subgroups include studying receptor associated kinase agents in genomically unstable tumors, and immune checkpoint inhibitors in MSI or EBV associated tumors given the higher mutational burden and expression of PDL-1 and PDL-2 ligands in these subgroups. A recent genomic analysis of 129 esophageal and GEJ adenocarcinomas identified three targetable subgroups, including enrichment for a BRCA like signature, tumors with a higher potential mutational burden, and tumors with a mutational pattern consistent with an aging imprint, with potential therapeutic implications including use of DNA damaging agents and immune checkpoint inhibitors (67). Stratification of patients on the basis of molecular profile will be obligatory in future trials given the potential for intrinsic biologic differences in these subsets.

Agents targeting immune checkpoint pathways mediated by the CTLA-4 and PD-1 pathways have also undergone recent extensive evaluation. Recent phase II and phase III trials indicate a small but consistent signal of activity for
anti PD-1 or PDL-1 agents in esophageal and GEJ cancers, with response rates ranging from 10–20% with a suggestion of higher response rates in patients with overexpression of PDL-1 (68,69). A recent phase III trial in gastric and GEJ cancer patients refractory to chemotherapy compared supportive care to treatment with the anti PD-1 agent nivolumab (69). Overall survival as well as response rate and progression free survival were improved for patients treated with nivolumab compared to placebo. These agents will likely be incorporated into clinical trials of neoadjuvant or adjuvant chemotherapy and radiation therapy.

Imaging during induction chemotherapy with PET scan may identify patients with early PET response who appear to have better clinical outcomes than PET non-responders, with higher rates of pathologic response, R0 resection, and potentially improved survival (70,71). A preliminary report of Cancer and Acute Leukemia Group B (CALGB)/Alliance trial 80803 indicated that use of PET scan to direct chemotherapy during preoperative chemoradiotherapy may enhance the rate of pathologic complete response (72). Patients were randomized to induction chemotherapy with either weekly carboplatin and paclitaxel or FOLFOX, and a PET scan was performed after 5–6 weeks of therapy. PET non-responders changed chemotherapy during radiation therapy to the alternative regimen, i.e., PET non-responders to carboplatin and paclitaxel were changed to infusional 5-FU and oxaliplatin during radiotherapy, and FOLFOX non-responders were changed to carboplatin and paclitaxel during radiotherapy. Pathologic complete responses in the cross over patients were observed in 17–19%, suggesting an improvement over an expected pathologic complete response of 5% from historical controls. Survival data from this trial are still pending.

**Conclusions**

Preoperative therapy with chemotherapy or chemoradiotherapy improves outcome over surgery alone and the debate about the role of radiation therapy with preoperative chemotherapy continues. The identification of agents targeting HER2, the VEGF pathway, and immune checkpoints has led to completed, ongoing, or planned clinical trials adding these agents to preoperative therapy. Genomic profiling has identified unique molecular subsets of these cancers, which may help guide new drug development and impact on the design of the next generation of neoadjuvant trials. The role of PET scan imaging to guide preoperative therapy continues to be studied in clinical trials.

**Acknowledgements**

None.

**Footnote**

*Conflicts of Interest:* Consulting work with Amgen, Bayer, AstraZeneca, Merck, Roche, Bristol Myers Squibb, Pieris, Lilly.

**References**


Cite this article as: Ilson DH. Adenocarcinoma of the esophagus: controversies and consensus. Chin Clin Oncol 2017;6(5):52. doi: 10.21037/cco.2017.09.02


